ADBIOTECH Co.,Ltd.
ADBiotech develops egg-derived IgY immune antibodies and scFv antibodies targeting avian influenza as an eco-friendly antibody biotech.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2000, ADBiotech listed on KOSDAQ in 2022 as an antibody-based biotech developing alternatives to vaccines and antibiotics. Its pipeline includes egg-derived IgY yolk antibodies, tissue-penetrating VHH (nanobody) antibodies for cattle, swine, and shrimp, the antibacterial/antifungal microbial agent BA01, and scFv antibodies targeting high- and low-pathogenic avian influenza (AI). It has secured about 200 antigens through chicken immunization and produces multi-pathogen antibodies using heterologous antibody technology; its scFv antibody is also used to neutralize the Sacbrood virus behind sacbrood disease in bees, and BA01 is supplied as paid samples to food-waste processor makers with a mass-production system in place.
Clinical trials
data.go.kr2 MFDS clinical trial authorisations · 2012–2018 (Phase 2 1 · Phase 2a 1)
- Phase 2애드리코(AD-lico)2018-01-04
7 trial sites
- Phase 2a애드리코(AD-lico)2012-12-24
4 trial sites
R&D and key agreements
Source: DART corporate disclosureIgY 면역난황항체 · 축산·수산·인체용 질병 예방 · 연구개발 · Derived from egg yolk; heterologous antibody technology achieves high antibody titer; about 200 antigens secured
VHH(나노바디) 항체 · 축우·양돈·새우 질병 치료 · 연구개발 · Simple antibody structure with strong tissue penetration, structural stability, and easy purification/mass production
미생물제 BA01 · 음식물처리기용, 닭 살모넬라 예방 · 유상샘플 공급 중, 대량양산체제 구축 · Patent acquired; mass-produced via in-house fermentation facility; supplying paid samples to food-waste processor manufacturers
scFv 항체(HA2 domain 특이항체) · 고·저병원성 조류인플루엔자(AI), 꿀벌 낭충봉아부패병(SBV) · 연구개발 · Uses chicken/rabbit spleen; binds low-mutation viral regions for variant resistance. The SBV antibody binds the Sacbrood virus envelope to neutralize it and block/treat infection in bee larvae
Companies in the same categoryPharma & CDMO
Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.
Founded in 1941 and listed on the KOSPI in 1975, Yuyu Pharma is a pharmaceutical company with a co-promotion agreement with Dong-A ST for Tanamin.
Founded in 1941 and listed on the KOSPI in 1975, Ildong Holdings is the holding company of the Ildong Pharmaceutical Group, overseeing pharmaceutical, aesthetic medical device, and drug development affiliates.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSPI-listed comprehensive pharmaceutical company specializing in blood products and vaccines, with FDA-approved immunoglobulin ALYGLO.
Founded 2005, KOSDAQ-listed 2022, BIO-FD&C develops plant-cell platform-based cosmeceutical materials and biopharma pipelines.
KOSPI-listed pharmaceutical company behind Coldwon cold medicine and Jangdaewon probiotics, developing a P-CAB drug pipeline.
Founded 2011, listed 2016 — Samsung Biologics is a biopharma CDMO with 785,000L capacity across five Songdo plants.
Founded in 2006 and listed on KOSDAQ in 2020, Genolution is a molecular diagnostics and RNAi company producing nucleic acid extraction reagents and devices.
KOSPI-listed comprehensive pharma company behind Amaryl diabetes drug and the USD 86.25M HL5101 anticancer out-license deal.
Founded and listed on KOSDAQ in 2015, Kolmar BioTech is a nonclinical CRO providing efficacy testing for anticancer and metabolic disease drug candidates.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition